Selskabets formål er i eller uden for Danmark at drive industri og handelsvirksomhed samt virksomhed med kapitalanlæg eller anden virksomhed, der efter bestyrelsens skøn har tilknytning til disse formål.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.1 mia. | -259 mio. | 2.6 mia. | 1.5 mia. | 690 | |
CVR: 25834844
Secondary names: FERTIN A/S, NordicCan A/S, NCP NextGen A/S
Previous names: JUT NR. 2128 A/S
4 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 164 companies in Fremstilling af andre fødevarer i.a.n.
Comparison is based on industry median values
Companies in the same industry and area
CVR 45975894
CVR 42202010
CVR 44059215
CVR 42686379
CVR 11802478
Fertin Pharma A/S is currently facing significant financial challenges, as evidenced by a substantial loss of 259 million DKK in 2024, following a trend of increasing losses over the past three years. Revenue has shown growth, rising from 892 million DKK in 2022 to 1.1 billion DKK in 2024, but this has not translated into profitability, with margins deteriorating sharply. The company's equity position has improved to 1.5 billion DKK, indicating a strong capital base, yet the negative profit trajectory raises concerns about operational efficiency and sustainability. Positioned within the food manufacturing sector, Fertin Pharma's ability to reverse its current financial trajectory will be critical for its future stability and growth.
AI-generated summary
companydata.dk